Literature DB >> 26422360

Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease.

Tomoko Oeda1, Atsushi Umemura1, Yuko Mori1, Satoshi Tomita1, Masayuki Kohsaka1, Kwiyoung Park1, Kimiko Inoue2, Harutoshi Fujimura2, Hiroshi Hasegawa3, Hiroshi Sugiyama1, Hideyuki Sawada4.   

Abstract

Homozygous mutations of the glucocerebrosidase gene (GBA) cause Gaucher disease (GD), and heterozygous mutations of GBA are a major risk factor for Parkinson's disease (PD). This study examined the impact of GBA mutations on the longitudinal clinical course of PD patients by retrospective cohort design. GBA-coding regions were fully sequenced in 215 PD patients and GD-associated GBA mutations were identified in 19 (8.8%) PD patients. In a retrospective cohort study, time to develop dementia, psychosis, wearing-off, and dyskinesia were examined. Survival time analysis followed a maximum 12-year observation (median 6.0 years), revealing that PD patients with GD-associated mutations developed dementia and psychosis significantly earlier than those without mutations (p < 0.001 and p = 0.017, respectively). Adjusted hazard ratios of GBA mutations were 8.3 for dementia (p < 0.001) and 3.1 for psychosis (p = 0.002). No statistically significant differences were observed for wearing-off and dyskinesia between the groups. N-isopropyl-p[(123)I] iodoamphetamine single-photon emission tomography pixel-by-pixel analysis revealed that regional cerebral blood flow was reduced in the bilateral parietal cortex, including the precuneus of GD-associated mutant PD patients, compared with matched PD controls without mutations.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical course; Glucocerebrosidase gene; MIBG scintigraphy; Parkinson's disease; Risk factor; SPECT

Mesh:

Substances:

Year:  2015        PMID: 26422360     DOI: 10.1016/j.neurobiolaging.2015.08.027

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  41 in total

Review 1.  GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.

Authors:  Parker H Johnson; Neal J Weinreb; James C Cloyd; Paul J Tuite; Reena V Kartha
Journal:  Mol Genet Metab       Date:  2019-10-23       Impact factor: 4.797

2.  Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy.

Authors:  Reena V Kartha; James Joers; Marcia R Terluk; Abigail Travis; Kyle Rudser; Paul J Tuite; Neal J Weinreb; Jeanine R Jarnes; James C Cloyd; Gülin Öz
Journal:  J Inherit Metab Dis       Date:  2019-12-17       Impact factor: 4.982

Review 3.  Integrating Patient Concerns into Parkinson's Disease Management.

Authors:  Shen-Yang Lim; Ai Huey Tan; Susan H Fox; Andrew H Evans; Soon Chai Low
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

Review 4.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

5.  Neuropsychiatric characteristics of GBA-associated Parkinson disease.

Authors:  Matthew Swan; Nancy Doan; Robert A Ortega; Matthew Barrett; William Nichols; Laurie Ozelius; Jeannie Soto-Valencia; Sarah Boschung; Andres Deik; Harini Sarva; Jose Cabassa; Brooke Johannes; Deborah Raymond; Karen Marder; Nir Giladi; Joan Miravite; William Severt; Rivka Sachdev; Vicki Shanker; Susan Bressman; Rachel Saunders-Pullman
Journal:  J Neurol Sci       Date:  2016-08-30       Impact factor: 3.181

6.  A Personalized Approach to Parkinson's Disease Patients Based on Founder Mutation Analysis.

Authors:  Nir Giladi; Anat Mirelman; Avner Thaler; Avi Orr-Urtreger
Journal:  Front Neurol       Date:  2016-05-10       Impact factor: 4.003

Review 7.  Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists.

Authors:  Daniel Martinez-Ramirez; Michael S Okun; Michael S Jaffee
Journal:  Neurodegener Dis Manag       Date:  2016-07-13

8.  Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models.

Authors:  S Pablo Sardi; Catherine Viel; Jennifer Clarke; Christopher M Treleaven; Amy M Richards; Hyejung Park; Maureen A Olszewski; James C Dodge; John Marshall; Elina Makino; Bing Wang; Richard L Sidman; Seng H Cheng; Lamya S Shihabuddin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

Review 9.  Association of gender and age at onset with glucocerebrosidase associated Parkinson's disease: a systematic review and meta-analysis.

Authors:  Qinghua Li; Yajun Jing; Peng Lun; Xia Liu; Peng Sun
Journal:  Neurol Sci       Date:  2021-04-10       Impact factor: 3.307

10.  Glucocerebrosidase and parkinsonism: lessons to learn.

Authors:  Ivanka Marković; Nikola Kresojević; Vladimir S Kostić
Journal:  J Neurol       Date:  2016-03-19       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.